Novo Nordisk resubmits higher-dosage Ozempic application to the FDA

After Novo Nordisk's previous FDA application was returned due to missing data, the firm has resubmitted a label expansion application for Ozempic on the world's largest market for diabetes products.

Photo: Stine Tidsvilde

On Friday, Novo Nordisk announced in a company statement that it has once again applied to the US Food and Drug Administration (FDA) for permission to start marketing the weekly diabetes treatment Ozempic in a higher dosage.

In February, the FDA declined to start processing a previous application since the health authority lacked information on factors such as a new production facility before granting the necessary approvals. Instead, the FDA sent a Refusal to File Letter in March.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs